RT Journal Article
SR Electronic
T1 Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159855
DO 10.1101/2020.07.22.20159855
A1 Schneeweiss, Maria C
A1 Leonard, Sandra
A1 Weckstein, Andrew
A1 Schneeweiss, Sebastian
A1 Rassen, Jeremy A
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.22.20159855.abstract
AB Objectives There is lack of clarity regarding the role of angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi) in interfering with the SARS-COV-2 binding on human cells and the resulting change in disease severity. We sought to assess the risk of hospitalization for COVID-19 and serious complications in current users of ARB or ACEi compared to users of dihydropyridine calcium channel blockers (dhpCCB).Design Cohort studySetting The analysis used de-identified, patient level data from HealthVerity, linking longitudinal data from US medical and pharmacy claims, which contain information on inpatient or outpatient diagnoses, procedures and medication dispensing.Participants We identified patients aged 40+ and free of chronic kidney disease (CKD) who were newly diagnosed COVID-19, between March 1, 2020 and May 30, 2020, and adherent to ACEi, ARB, or dhpCCB therapy.Interventions Current use of an ACEi, ARB, or dhpCCB.Main outcome measures We compared the 30-day risk of hospitalization for COVID-19 and serious complications.Results Of 24,708 patients identified, 7,571 were current users of an ARB, 8,484 of an ACEi, and 8,653 of a dhpCCB. The unadjusted 30-day risk of hospitalization for COVID-19 was 2.66% among ARB users, and 2.90% among ACEi users and 3.68% in dhpCCB users. In the PS-matched cohort, the risk of hospitalization among ARB users was 17% lower as compared to dhpCCB (RR=0.83; 0.68-1.00), and the risk among ACE users was 10% lower as compared to dhpCCB (RR=0.90; 0.76-1.07). When including patients with pre-existing CKD, the protective effect of ARB (RR= 0.74; 0.62-0.88) and ACEi (RR=0.84; 0.71-0.99) was more pronounced.Conclusions This cohort study showed that neither ARB nor ACEi use increase the risk of severe COVID-19 disease among those infected, and instead suggests that current use of ARB may offer a protective effect. This study found no evidence to support the discontinuation of ARB/ACEi therapy.Competing Interest StatementAll authors have completed the Unified Competing Interest form, available on request from the corresponding author, and declare: Dr. Schneeweiss M has no relevant financial interests to report. Ms. Leonard is employee of HealthVerity Inc. and holds equity. Dr. Schneeweiss S is the principal investigator of investigator initiated grants to the Brigham and Women Hospital from the FDA, NIH, PCORI, Bayer, Vertex, and Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion, a software manufacturer of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women Hospital and Partners HealthCare System in accordance with their institutional compliance policies. Drs. Weckstein and Rassen are employees of Aetion Inc. and hold equity.Funding StatementNo further funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the New England IRB (#1-9757-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified patient level study data can be made available for inspection. All analyses from the raw patient-level data are recorded with audit trails and can be reviewed on request.